Tag
Despite proven benefits, medications for alcohol use disorder remain underprescribed at hospital discharge. This study identifies hospitalization and patient factors influencing new prescriptions, highlighting opportunities to enhance AUD t
Alcohol-associated hepatitis (AH) carries high morbidity and mortality, with no approved therapies addressing both liver injury and alcohol misuse. This article explores integrated trial designs using composite endpoints combining liver and
Few US adults with alcohol or opioid use disorder reported addiction pharmacotherapy use in 2022-2023. Pharmacotherapy receipt was linked to increased healthcare utilization, underscoring the need for early outpatient intervention strategie
This Swedish register-based study reveals that GLP-1 receptor agonists are associated with significantly reduced hospitalisations for alcohol and substance use disorders during treatment, with some lasting benefits after discontinuation of
A hospital-based screening and treatment program for unhealthy alcohol use was feasible in a diverse safety-net population and was linked to short-term reductions in alcohol risk scores, especially among patients who received follow-up and
VHA study reveals only 30% of veterans hospitalized for AUD receive evidence-based medications during or shortly after hospitalization, with significant variation across hospitals and demographic factors influencing prescription rates.
This study quantifies the heightened risk of alcohol-related liver disease, cancer, cardiovascular mortality, and all-cause death among individuals receiving treatment for alcohol use disorder compared to the general population, emphasizing
This article reviews emerging evidence on how general intelligence and cognitive performance relate to the risk of alcohol use disorder, integrating large-scale population data, genetic analyses, and the role of educational attainment acros
